Kilburn Q1 FY27: consolidated PAT -39% YoY, revenue -9% as margins compress
PAT -38.57% YoY · revenue -9.48% · margins compressing
₹116.99 Cr
-9.48% YoY
₹13.09 Cr
-38.57% YoY
10.86%
-5.3pp YoY
₹2.39
Kilburn Engineering's consolidated revenue fell 9.5% YoY to ₹116.99 Cr (₹129.25 Cr in Q1 FY26) and 38.2% QoQ from a seasonally strong ₹189.18 Cr in Q4 FY26. Consolidated PAT dropped 38.6% YoY to ₹13.09 Cr (₹21.31 Cr) and 47.3% QoQ (₹24.86 Cr); EPS fell a steeper 46.2% YoY to ₹2.39 (₹4.44) since the equity base grew ~15.6% after warrant conversion. Standalone (parent-only) results were markedly weaker — revenue down 37.8% YoY to ₹58.90 Cr and PAT down 64.9% YoY to ₹5.17 Cr — so the group's smaller decline was driven almost entirely by the subsidiaries; the >3% standalone-consolidated divergence means readers should not read the standalone print in isolation.
Q1 FY-2027 vs prior quarters
Margins compressed on both counts: consolidated OPM (EBITDA/revenue) fell to 17.7% from 25.8% a year ago and 19.9% last quarter, while NPM slid to 10.9% from 16.2% YoY. The compression traces to operating deleverage on lower volumes — materials consumed rose to 48.5% of revenue from 41.6% YoY, and employee costs to 16.3% from 12.6% — rather than any one-off item; no exceptional items are disclosed in either statement. Management's own release, titled 'Revenue Down, Order Inflows Strong,' attributes the topline dip to 'near-term geopolitical uncertainties affecting the timing of customer decisions' rather than demand loss, and points to order momentum: the ₹70.2 Cr Casale order and fertilizer orders crossing ₹170 Cr booked in June 2026 sit in the order book but hadn't converted to Q1 billing.
The stock went into the print at ₹357.8, down 20.1% over the past month of trading.
What the summary numbers don't show
Paid-up equity capital rose to ₹56.00 Cr from ₹52.96 Cr after conversion of 30.375 lakh warrants for ₹96.82 Cr; remaining 2.35 lakh warrants lapsed with ₹2.50 Cr forfeiture money retained
Management is targeting a top-line growth of 20% to 25% for the current financial year, aiming for revenues between INR750 crores to INR800 crores, and expects to maintain EBITDA margins above 20%, specifically targeting 22-23%. For the longer term, they are focused on achieving INR1,000 crores in revenue by FY28. Cape
— This quarter: missed
There is no formal sell-side estimate on record for this print — Kilburn carries thin analyst coverage and no consensus figure was found — so vsStreet is unknown. Against management's own FY27 guidance from the Q4 FY26 call (20-25% revenue growth to ₹750-800 Cr, 22-23% EBITDA margin, capex expansions completing by Q2 FY27), this quarter's YoY revenue decline puts the company well behind the pace needed for the full-year target, even allowing that one quarter is not conclusive on its own. The quarter's other developments — designation of two Senior Management Personnel and a Monitoring Agency report for Q1 FY27 — are governance/compliance items with no direct bearing on the numbers.
W1
Capex-driven capacity expansion targeted for completion by Q2 FY27 (per Q4 FY26 concall) — watch for ramp-up commentary at the Aug 17, 2026 earnings call
W2
FY27 guidance of ₹750-800 Cr revenue (20-25% growth) now needs a much steeper ramp in the remaining nine months after Q1's 9.5% YoY decline — track whether the ₹70.2 Cr Casale and >₹170 Cr fertilizer orders convert to Q2 billing
W3
OPM compressed to 17.7% from 25.8% YoY against management's 22-23% FY27 EBITDA margin target — watch for margin recovery as volumes normalize
Both statements clear/legible, tables tie out exactly (totalIncome and PBT-tax both match reported PAT). Standalone PAT fell far more (-64.9% YoY) than consolidated (-38.6% YoY) — subsidiaries (Monga Strayfield, Strayfield UK, M.E Energy, Kilburn East End) cushioned the group number. No exceptional items flagged; 30.375 lakh warrants converted to equity in the quarter for ₹96.82 Cr.
Execution Delays Derail Near-Term; ₹700Cr Target at Risk
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 5/10
Grade C
Missed YoY targets this quarter; FY27 ₹700Cr reaffirmed but execution risk elevated; margin target lower than prior 22-23% aspiration.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 revenue miss (-9.5% YoY) and PAT collapse (-38.6% YoY) contradicts bullish narrative on demand. ₹700Cr FY27 target highly dependent on H2 acceleration under customer delays and geopolitical headwinds. Margin guidance compressed from prior 22-23% to 20%.
₹117 Cr
Revenue · −9.5% YoY₹13.1 Cr
Reported PAT · −38.6% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Underlying demand healthy, not deterioration
OVERSTATEDRevenue down 9.5% YoY, PAT down 38.6% YoY despite margin hold. Narrative doesn't match delivered numbers.
Maintaining 20% operating margin in low-revenue quarter
MISSDelivered OPM 17.7% vs claimed 20.1% EBITDA. 2.4% gap unexplained.
₹700Cr FY27 achievable with H2 acceleration
OVERSTATEDNeed ₹583Cr in remaining 9 months (₹194Cr/qtr avg). Customer delays ongoing. Order book only ₹485Cr.
Strong underlying business, only timing issue
OVERSTATEDYoY & QoQ declines material (-9.5% rev, -38.6% PAT). Timing alone doesn't explain magnitude.
Earnings quality
What changed since the last call
Margin target compressed
DowngradePrior FY26 guidance: 22-23% EBITDA target. FY27: now 20%. A 200-300 bps haircut despite cost discipline claims.
Revenue growth reversed
DowngradePrior guidance: 20-25% growth aiming for ₹750-800Cr FY26. FY27 guidance: ₹700Cr, implying flat-to-negative growth trajectory.
FY28 guidance withdrawn
WithdrawnPrior: ₹1,000Cr by FY28 (explicit). Current: ₹1,000Cr as 'medium-term aspiration' without timeline. Pushed out indefinitely.
The Q&A
Moderate pressure in Q&A. Analyst Andrey Purushottam criticized inquiry pipeline disclosure as 'misleading' and suggested sticking to order book; management took note but defended practice. Daksh Malhotra pressed on miss vs prior 25% growth guidance; management cited regulatory delays (nuclear approvals) and order mix (long-cycle projects). Some deflection on large waste heat recovery order details (Vijaysanker's audio issues). Overall: management held ground but conceded on transparency critique.
Capital allocation — Sagar Shah, Spark Capital PWM
AnsweredCapex for ₹1,000Cr revenue capacity. Balance sheet now debt-free. M&A always explored, but organic growth priority given strong sector tailwinds.
Order momentum — Sagar Shah, Spark Capital PWM
Partial₹4,000Cr inquiry pipeline. Fertilizer new orders bagged, more coming. Nuclear, ferrous alloy showing traction. Middle East delays due to conflict, but no current orders there.
Large order delays — Bhavya Nahar, Tamohara Investments
DodgedDrying solutions expected Q2 close. Waste heat recovery: Vijaysanker (audio issues, no answer). Amritanshu covered ferrous alloy inquiries instead.
Execution delays root cause — Sameer Chheda, Prince Polyplast
AnsweredBoth. Customers delaying approvals on drawings, QA inspections. Execution cycle extends; some jobs slipping 1-2+ quarters. Kilburn has no holdups at its end.
Margin impact of delays — Sameer Chheda, Prince Polyplast
AnsweredLock 80% raw material within 72 hours. Endeavor to seek customer compensation for delay-induced escalation, but success varies on contract terms.
Miss vs prior guidance — Daksh Malhotra, Aardiv Global
PartialOrder mix: nuclear jobs require NPCIL approvals (slow). Greenfield projects stuck on land/environmental clearances. Underlying business strong but execution timing dependent on customer/regulatory calendars.
Inquiry pipeline critique — Andrey Purushottam, Cogito Advisors
DodgedSuggestion taken. We will review how we communicate going forward. Currently we report both intake and closing orders.
Guidance
FY27: ₹700Cr consolidated revenue (second-half weighted)
MediumBased on deferred orders, visible order book, scheduled deliveries. But Q1 miss and ongoing customer delays raise execution risk.
FY27 EBITDA: 20% (vs 22-23% prior aspiration)
MediumMargin compression 200-300 bps. Q1 delivered 17.7% OPM below target. Customer delays and escalation pressures evident.
Expansions: Kilburn & M.E. Energy complete by Oct 2026. Monga Strayfield ongoing. Designed for ₹1,000Cr capacity.
HighAdvanced stage, funded via ₹98Cr raise. Medium-term objective to enable multi-fold growth.
Risks the call surfaced
Execution risk
High₹700Cr FY27 requires ₹583Cr in 9 months (₹194Cr/qtr avg). Q1 was ₹117Cr. Customer approval delays affecting 3-4 projects; geopolitical headwinds cited. Order book ₹485Cr insufficient without new inflows.
Geopolitical headwinds
MediumMiddle East conflict extended customer decision cycles. Some large inquiries deferred (petrochem, O&G). Management hopes H2 normalization but admits uncertainty persists.
Regulatory approval delays
MediumNuclear orders require NPCIL/Heavy Water Board approvals (lengthy process). Greenfield projects stuck on environmental clearances & land acquisition (carbon black sector). Some jobs shifting 1-2+ quarters.
Order conversion risk
Medium₹4,000Cr inquiry pipeline repeatedly cited but unproven. Conversion depends on customer decisions, project economics, timing. YTD inflows ₹190Cr vs ₹800Cr target shows gap.
Margin sustainability
MediumFixed-price contracts expose to material cost inflation. Management books 80% raw materials within 72 hours but customer approval delays push execution timelines, eroding margins. OPM 17.7% vs 20% target shows miss.
Management
Score 6/10. Transparent on headwinds (customer delays, geopolitical impact, regulatory bottlenecks) but defensive tone evident. Acknowledged inquiry pipeline criticism from Andrey Purushottam mid-call; took it gracefully but didn't change disclosure. Some technical limitation (Vijaysanker's audio) prevented detail on waste heat recovery orders. Mixed track record. Prior guidance (₹750-800Cr FY26, 20-25% growth, 22-23% margins) now revised downward (₹700Cr FY27, flat growth, 20% margins). Current quarter missed YoY expectations. FY28 guidance explicitly withdrawn.
1 · Q2 FY27 (Sep-Oct 2026)
Capex expansions at Kilburn & M.E. Energy complete; new capacity orders expected
2 · H2 FY27 (Oct-Mar 2027)
Deferred project executions resume; customer approvals clear per mgmt. Geopolitical headwinds ease.
3 · FY27 closing
₹800Cr order inflows target; conversion of ₹4,000Cr inquiry pipeline to firm orders at risk
Margin guidance compressed from prior 22-23% to 20%.
Orders Don't Match Rhetoric: Kilburn's ₹700Cr Target at Risk
Revenue fell 9.5% year-on-year and profit collapsed 38.6%, yet management insists ₹700 crore full-year is achievable. The order book says otherwise — and the market has already priced in the miss.
₹117 Cr
–9.5% YoY; only 16.7% of full-year ₹700Cr target
₹13.1 Cr
–38.6% YoY; fixed-cost absorption pressure
₹485 Cr
Gap: ₹215Cr+ needed by year-end
₹700 Cr
Requires ₹583Cr in next 9 months (₹194Cr/qtr avg)
The core gap: orders don't match the story
Kilburn delivered ₹117 crore in Q1 FY27, down 9.5% year-on-year. Worse, net profit sank 38.6%—from ₹21.4 crore to ₹13.1 crore—a decline nearly four times steeper than the revenue miss. This disproportionate PAT decline signals fixed-cost absorption strain or adverse margin mix in the lower-revenue execution phase. Yet management reaffirmed ₹700 crore full-year revenue is achievable. That implies ₹583 crore in the remaining nine months, or ₹194 crore per quarter on average—66% above Q1's run-rate, all while citing persistent customer approval delays and geopolitical headwinds.
Margin claim vs. delivered: a 2.4 percentage-point gap
Management claimed a 20.1% EBITDA target during the call. Q1 delivered 17.7% OPM—a 2.4 percentage-point shortfall left unexplained in follow-up remarks. Wider context: prior FY26 guidance had targeted 22–23% EBITDA margins. The new ₹700 crore guidance assumes 20%, a 200–300 basis-point haircut from prior aspiration. Cost discipline is documented (80% raw materials locked within 48–72 hours), but the gap between claimed and delivered margins on a revenue-light quarter—where cost control should shine—raises an earnings quality flag.
Underlying demand healthy; execution delays are timing issue
OverstatedRevenue –9.5% YoY, PAT –38.6% YoY. Magnitude doesn't square with 'timing alone.'
Maintaining 20% operating margin target
ContradictedDelivered 17.7% OPM; 2.4pp gap vs. claimed 20.1% EBITDA mid-call.
₹700Cr FY27 achievable via H2 acceleration
OverstatedOrder book ₹485Cr, need ₹215Cr+ new orders. YTD inflows ₹190Cr vs ₹800Cr target (only 24% fill).
₹1,000Cr medium-term aspiration; capex underway
WithdrawnPrior guidance: ₹1,000Cr by FY28 (explicit). Now: no timeline, no FY28 target stated.
What changed on this call
Revenue growth: 20–25% target → flat/down to ₹700Cr
EBITDA margin aspiration: 22–23% → 20% (200–300 bps haircut)
FY28 revenue: ₹1,000Cr (explicit) → 'medium-term aspiration' (no date)
Capex expansions (Kilburn, M.E. Energy): on track for Oct 2026 completion
The debate
Bull-bear ledger
Fertilizer & nuclear sector demand structural and multi-year
Capex expansions on track; funded via ₹98Cr equity raise (balance sheet debt-free)
Differentiated technical franchise in specialized project engineering
Analyst Andrey Purushottam publicly challenged inquiry pipeline; management took note but didn't change disclosure
Q1 revenue –9.5% YoY, PAT –38.6% YoY; consistent miss pattern
Order book insufficient; ₹4,000Cr inquiry pipeline unproven; YTD inflows only 24% of annual target
Margin guidance compressed 200–300 bps; OPM delivered 2.4pp below target
Customer approval delays (3–4 projects), geopolitical headwinds, regulatory delays endemic to sector
How the street is positioned
The stock closed at ₹363 on 19 Aug 2026, down 39.25% from its all-time high of ₹597.5. It trades below its 20-day (₹398.6), 50-day (₹442.79), and 200-day (₹505.56) moving averages—a sustained downtrend. RSI sits at 22.4, deep in oversold territory, typically a capitulation signal. Yet the post-result price action tells the real story: the day after the result announcement (14 Aug), the stock fell 2.88% on 68.6% delivery volume (institutional offload), then rallied 1.45% three days later—a modest recovery that never took hold. Translation: the market repriced and held. Fundamental disappointment is already baked in.
FII ownership has ticked down 11 basis points quarter-on-quarter (1.24% → 1.13%), a small but directional trim by foreign institutional investors. DII ownership is steady at 7.64%; promoter holding edged down 124 basis points (45.77% → 44.53%), likely due to ₹98 crore equity dilution. No insider buying or promotional accumulation near the lows—a red flag when a stock is 39% off its highs.
Taken together: the market has priced in both the miss and the execution risk. A ₹700 crore full-year target on a ₹117 crore Q1 base, with order book ₹485 crore and geopolitical headwinds cited by management, is not valued as a near-term recovery.
Risks ranked by how much they should concern a holder
Execution risk: ₹700Cr target unachievable
HighNeed ₹583Cr in 9 months (₹194Cr/qtr) vs Q1 ₹117Cr. Order book ₹485Cr, need ₹215Cr+ new orders. 3–4 projects stuck on customer approvals with no firm timeline. If H2 ≈ Q1 at ₹235Cr, full-year ≈₹352Cr (50% miss). Forward guidance credibility collapses.
Order conversion from ₹4,000Cr pipeline unproven
HighPipeline is 10:1 speculative to Q1 run-rate. Conversion depends on customer decisions, project economics, geopolitical normalization. YTD inflows ₹190Cr vs ₹800Cr target shows only 24% fill. If pipeline converts <15%, ₹700Cr target fades.
Margin compression: 20% target already at risk
MediumQ1 delivered 17.7% OPM vs 20% claimed. Fixed-price contracts expose to material cost inflation; customer delays push timelines, eroding margins. If margins compress another 200–300 bps, full-year PAT sags below FY26 despite flat/higher revenue.
Geopolitical & regulatory delays endemic
MediumMiddle East conflict extended decision cycles; zero current orders in petrochem/O&G. Nuclear approvals (NPCIL) slow; environmental clearances on greenfield projects backlogged. Some jobs slipping 1–2+ quarters. Structural constraint, no quick fix.
Management credibility on guidance
MediumPrior FY26 guidance (₹750–800Cr, 20–25% growth, 22–23% EBITDA) now downgraded or withdrawn (₹700Cr, flat growth, 20% margins, FY28 no longer stated). Analyst Andrey Purushottam called inquiry pipeline 'misleading.' Track record eroding.
What to watch next
1 · Q2 order inflows and order-book trajectory
FY27 target is ₹800Cr; YTD only ₹190Cr. Q2 needs ≥₹300Cr minimum to keep ₹700Cr credible. Watch for fertilizer new orders (mgmt said 'more expected Q2 close'), waste heat recovery closures (Vijaysanker's audio issue masked Q1 detail). If Q2 inflows <₹250Cr, ₹700Cr is mathematically gone.
2 · Capex completion and capacity ramp
Kilburn & M.E. Energy expansions expected complete by Oct 2026. Watch for announcement of orders won as a result of new capacity. If expansions complete but order pipeline doesn't follow, capacity underutilization risk rises sharply. Capex credibility is on the line.
3 · Customer approval deferrals: reset or rollover?
3–4 projects stuck on customer approvals (drawings, QA, regulatory clearances). Management claimed H2 resumption once geopolitical headwinds ease. Track whether these projects actually begin execution H2 or slip into FY28. This is the binary on whether ₹700Cr is feasible or not.
The honest read
Kilburn is not in crisis. Long-term sectoral tailwinds in fertilizer, nuclear, and data center infrastructure remain intact. Capex is real, balance sheet is clean, technical franchise is differentiated. But this is a step-back quarter, not a setup for step-change growth.
Q1 misses—revenue –9.5% YoY, PAT –38.6%, margins below target—are not noise. They align with what management itself acknowledges: customer approval delays, geopolitical headwinds, order book that can't support ₹700 crore full-year without significant new wins. ₹700 crore is possible but not probable on this order trajectory.
The number to track from here is order inflows—not inquiries, inflows. ₹800 crore full-year requires ₹610 crore in the next eight months. At current trajectory (₹190Cr YTD = ₹95Cr per half-year), the gap is ₹515 crore. That's not a margin of error; it's the entire miss.
The market's 39% drawdown and 22-point RSI have priced in deep skepticism. That skepticism looks warranted. A bounce requires either a ₹300Cr+ order blowout in Q2 or a material reset in expectations. Until then, this is a Hold.